-
1 Comment
Oryzon Genomics S.A is currently in a long term uptrend where the price is trading 6.6% above its 200 day moving average.
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.
Oryzon Genomics S.A's total revenue sank by nan% to $0 since the same quarter in the previous year.
Its net income has dropped by 19.7% to $-1M since the same quarter in the previous year.
Based on the above factors, Oryzon Genomics S.A gets an overall score of 2/5.
| Industry | Biotechnology |
|---|---|
| Sector | Healthcare |
| ISIN | ES0167733015 |
| CurrencyCode | EUR |
| Exchange | F |
| Beta | 0.99 |
|---|---|
| Market Cap | 124M |
| Dividend Yield | 0.0% |
| Target Price | None |
| PE Ratio | None |
Oryzon Genomics S.A., a clinical phase biopharmaceutical company, engages in the discovery and development of epigenetics-based therapeutics for patients with cancer and CNS disorders. Its clinical phase compounds include iadademstat (ORY-1001), a selective LSD1 inhibitor that is in Phase II trials for oncology; and vafidemstat (ORY-2001), a CNS-optimized LSD1 inhibitor, which is in Phase II trials for the treatment of CNS and psychiatric diseases. Its product candidates also comprise ORY-3001, an LSD1 inhibitor that is in preclinical development for the treatment of non-oncological diseases. The company was founded in 2000 and is based in Cornellà de Llobregat, Spain.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for ORN.F using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2024
